The Effect of Desensitizing Agents in In-home or In-office Dental Bleaching

December 9, 2014 updated by: Camila Tirapelli, University of Sao Paulo

Evaluating Remineralizers and Desensitizers Agents in Dental Bleaching Treatment: in Vitro and in Vivo Study

The aim of this project is to evaluate in vitro and in vivo the effect of dental bleaching agents, carbamide peroxide 16% (T1) and hydrogen peroxide 35% (T2) together with desensitizers/remineralizer agents, Sensodyne® dentifrice (D1); experimental dentifrice with 7,5% of Biosilicate micro-particles (D2); Odontis RX® dentifrice (D3); Sorriso® dentifrice (D4); Biosilicate micro-particles paste, 1:1 (D5), Desensebilize Nano P (D6), bioglass type 45S5 paste, 1:1 (D7); GC= distilled water, in the experimental groups: T1/D1; T1/D2; T1/D3; T1/D4; T1/D5; T1/D6; T1/D7; T1/GC e T2/D1; T2/D2; T2/D3; T2/D4; T2/D5; T2/D6; T2/D7; T2/GC. In the in vitro study, microhardness and roughness measurements, and images using scanning electron microscopy (SEM) will be made on samples of bovine dental enamel and dentin (4x4x3mm; n=10 per group) before and after the treatment with the bleaching gels (T1= 14 days/ 04 hours/day; T2=single session) and the desensitizers/remineralizer agents. In the clinical study, the volunteers (n=10 per group) will be evaluated regarding dentin hypersensitivity (DH), using visual analogue scale, before the beginning of the treatments (T1 and T2) and during the next 14 days (1º, 3º, 7º, 10 º e 14º days) in which the desensitizers/remineralizer agents (there´s no control group in the clinical experiments) will be applying. Data will be analysed intra and inter-group, statistically.

Study Overview

Status

Completed

Detailed Description

Background. Tooth sensitivity (TS) is a common side effect of tooth bleaching. The authors conducted a study to evaluate the efficiency of experimental desensitizing agents in reducing TS caused by bleaching agents.

Methods. To test experimental desensitizing agents in TS caused by dental bleaching the authors selected 113 participants without TS and randomly treated them with T1-16% carbamide peroxide (14 days) or T2-35% hydrogen peroxide (single session). The period of the study was 14 days. Participants (in T1 and T2) used domestic-use (DU) or in office (IO) desensitizers (D): Control Group; (DU)- experimental dentifrice with 7,5% of Biosilicate micro-particles-(D1); Sensodyne® dentifrice-(D2); (DU)-Odontis RX Sensiblock® dentifrice-(D3); (IO)-Biosilicate micro-particles paste, 1:1-(D4); (IO)-bioglass type 45S5 paste, 1:1 (D6); (IO)-Desensebilize Nano P-(D6). On days 1, 3, 7, 10 and 14, the authors received the participants to apply IO desensitizers and to record TS with Visual Analogue Scale (VAS). Data was analyzed with two-way ANOVA (considering time and desensitizing as factors) and post-hoc Bonferroni test (α=0.05).

Results. The use of experimental desensitizing agents G2 and G5 did not cause significantly difference in TS comparing to baseline. TS was not significantly different when G2 was used after 16% carbamide peroxide and G5 after 35% hydrogen peroxide application. Self-perception TS values were significantly (p<0.001) higher than recorded VAS.

Conclusions. Experimental desensitizing agents containing Biosilicate® can prevent TS caused by bleaching agents: in dentifrice form when associated to 16% carbamide peroxide and in paste, when 35% hydrogen peroxide is used.

Study Type

Interventional

Enrollment (Actual)

113

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • São Paulo
      • Ribeirão Preto, São Paulo, Brazil, 14040904
        • University of Sao Paulo -Ribeirao Preto Campus

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients male or females, aged between 18 and 40 years.
  2. Smokers and nonsmokers.
  3. Patients with good general health.
  4. Patients with good oral health (no changes in hard or soft tissues).
  5. Have a minimum of 24 permanent teeth present and no restorations on anterior teeth.

Exclusion Criteria:

  1. Patients with a medical history marked by chronic use of analgesics, anti-inflammatory and psychotropic drugs.
  2. Patients with braces or prostheses or restorations on anterior teeth.
  3. Patients with periodontal disease or poor oral hygiene.
  4. Patients with prior tooth sensitivity or have made use of desensitizing agents in the last three months.
  5. Patients who are pregnant or nursing.
  6. Patients with eating disorders or dieting too acidic.
  7. Systemic conditions that predispose to tooth sensitivity.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: FACTORIAL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Desensitizing therapy
14 groups (7 treated with in-office dental bleaching and 7 treated with home-use dental bleaching) . There will be 7 different types of dessensitizing agents that will be used together with the dental bleaching treatment
Home-use or in-office dental bleaching was performed in patients that received different types od desensitizing therapy
Other Names:
  • Whitness Perfect®
  • Whitness HP®
EXPERIMENTAL: Dental Bleaching
2 groups of dental bleaching treatment - 16% carbamide peroxide and 35% peroxide
Participants (in T1 and T2) used domestic-use (DU) or in office (IO) desensitizers (D): Control Group; (DU)- experimental dentifrice with 7,5% of Biosilicate micro-particles-(D1); Sensodyne® dentifrice-(D2); (DU)-Odontis RX Sensiblock® dentifrice-(D3); (IO)-Biosilicate micro-particles paste, 1:1-(D4); (IO)-bioglass type 45S5 paste, 1:1 (D6); (IO)-Desensebilize Nano P-(D6).
Other Names:
  • Dentifrice of Biosilicate
  • Sensodyne® dentifrice
  • Odontis RX Sensiblock
  • Biosilicate micro-particles paste, 1:1
  • Bioglass type 45S5 paste, 1:1
  • Desensebilize Nano P

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dentin hypersensitivity
Time Frame: Baseline
The pain caused by dentin hypersensitivity was measured by stimulating cervical region of the teeth with a blast of air from a triple seringe and the patient will relate his/her pain in accordance with a visual analog scale (VAS) which consists of a 1 to 10 scale where the patients recorded their dentin hypersensitivity when stimulated. Dentin hypersensitivity (DH) was measured, using visual analogue scale, before the beginning of the treatments (baseline -T1 and T2) and during the next 14 days (1º, 3º, 7º, 10 º e 14º days)
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dentin hypersensitivity
Time Frame: Day 1
The pain caused by dentin hypersensitivity was measured by stimulating cervical region of the teeth with a blast of air from a triple seringe and the patient will relate his/her pain in accordance with a visual analog scale (VAS) which consists of a 1 to 10 scale where the patients recorded their dentin hypersensitivity when stimulated. Dentin hypersensitivity (DH) was measured, using visual analogue scale, before the beginning of the treatments (baseline -T1 and T2) and during the next 14 days (1º, 3º, 7º, 10 º e 14º days)
Day 1
Dentin hypersensitivity
Time Frame: Day 3
The pain caused by dentin hypersensitivity was measured by stimulating cervical region of the teeth with a blast of air from a triple seringe and the patient will relate his/her pain in accordance with a visual analog scale (VAS) which consists of a 1 to 10 scale where the patients recorded their dentin hypersensitivity when stimulated. Dentin hypersensitivity (DH) was measured, using visual analogue scale, before the beginning of the treatments (baseline -T1 and T2) and during the next 14 days (1º, 3º, 7º, 10 º e 14º days)
Day 3
Dentin hypersensitivity
Time Frame: Day 7
The pain caused by dentin hypersensitivity was measured by stimulating cervical region of the teeth with a blast of air from a triple seringe and the patient will relate his/her pain in accordance with a visual analog scale (VAS) which consists of a 1 to 10 scale where the patients recorded their dentin hypersensitivity when stimulated. Dentin hypersensitivity (DH) was measured, using visual analogue scale, before the beginning of the treatments (baseline -T1 and T2) and during the next 14 days (1º, 3º, 7º, 10 º e 14º days)
Day 7
Dentin hypersensitivity
Time Frame: Day 10
The pain caused by dentin hypersensitivity was measured by stimulating cervical region of the teeth with a blast of air from a triple seringe and the patient will relate his/her pain in accordance with a visual analog scale (VAS) which consists of a 1 to 10 scale where the patients recorded their dentin hypersensitivity when stimulated. Dentin hypersensitivity (DH) was measured, using visual analogue scale, before the beginning of the treatments (baseline -T1 and T2) and during the next 14 days (1º, 3º, 7º, 10 º e 14º days)
Day 10
Dentin hypersensitivity
Time Frame: Day 14
The pain caused by dentin hypersensitivity was measured by stimulating cervical region of the teeth with a blast of air from a triple seringe and the patient will relate his/her pain in accordance with a visual analog scale (VAS) which consists of a 1 to 10 scale where the patients recorded their dentin hypersensitivity when stimulated. Dentin hypersensitivity (DH) was measured, using visual analogue scale, before the beginning of the treatments (baseline -T1 and T2) and during the next 14 days (1º, 3º, 7º, 10 º e 14º days)
Day 14

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Camila Tirapelli, PhD, University of Sao Paulo

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2011

Primary Completion (ACTUAL)

June 1, 2013

Study Completion (ACTUAL)

June 1, 2013

Study Registration Dates

First Submitted

September 21, 2011

First Submitted That Met QC Criteria

December 9, 2014

First Posted (ESTIMATE)

December 12, 2014

Study Record Updates

Last Update Posted (ESTIMATE)

December 12, 2014

Last Update Submitted That Met QC Criteria

December 9, 2014

Last Verified

December 1, 2014

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dentin Hypersensitivity

Clinical Trials on Dental bleaching

Subscribe